种族和民族多样化的美国参与者在早期阿尔茨海默病中来卡奈单抗和埃伦贝司他安慰剂对照双盲随机2期和3期试验的合格率
研究利用4项早期阿尔茨海默病随机双盲安慰剂对照试验的筛选数据,评估美国不同种族和民族群体的入选合格率。共筛选10804名美国参与者,以非西班牙裔白人为参照,西班牙裔黑人、西班牙裔白人、非西班牙裔亚洲人和非西班牙裔黑人在淀粉样蛋白生物标志物标准上的不合格概率更高。结论认为 eligibility 差异可能导致某些少数种族和民族群体在早期AD试验中代表性不足。
要点
- 西班牙裔白人淀粉样蛋白生物标志物不合格的OR为4.15(95%CI 3.58-4.83),高于非西班牙裔白人。
- 非西班牙裔黑人淀粉样蛋白生物标志物不合格的OR为3.75(95%CI 2.80-5.06)。
- 西班牙裔黑人OR为3.20(95%CI 2.11-4.88),非西班牙裔亚洲人OR为2.35(95%CI 1.23-4.55)。
核心结论
- eligibility 差异可能促成某些少数种族和民族群体在早期阿尔茨海默病试验中代表性不足。
- 淀粉样蛋白生物标志物合格是确认阿尔茨海默病诊断和接受降淀粉样蛋白药物治疗的要求,且在不同种族和民族群体间存在差异。
研究设计与样本
- 使用4项早期阿尔茨海默病随机双盲安慰剂对照临床试验的筛选数据。
- 评估不同种族和民族群体的合格率,并控制其他人口学协变量。
- 每项试验均采用正电子发射断层扫描和/或脑脊液评估脑淀粉样蛋白病理,以及早期阿尔茨海默病试验的典型入选标准。
主要发现
- 共筛选10804名美国参与者:西班牙裔黑人有193人(2%),西班牙裔白人有2624人(25%),非西班牙裔亚洲人有118人(1%),非西班牙裔黑人有696人(7%),非西班牙裔白人有7017人(65%)。
- 排除156名不符合上述分类的参与者的数据。
- 控制年龄、性别和试验后,以非西班牙裔白人为参照组,西班牙裔黑人淀粉样蛋白生物标志物标准不合格的OR为3.20(95%CI 2.11-4.88)。
- 西班牙裔白人淀粉样蛋白生物标志物标准不合格的OR为4.15(95%CI 3.58-4.83)。
- 非西班牙裔亚洲人淀粉样蛋白生物标志物标准不合格的OR为2.35(95%CI 1.23-4.55);非西班牙裔黑人OR为3.75(95%CI 2.80-5.06)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Many factors contribute to inadequate diversity in Alzheimer disease (AD) clinical trials. We evaluated eligibility rates among racial and ethnic groups at US sites in large global multisite trials in early AD. METHODS: Using screening data from 4 randomized, double-blind, placebo-controlled clinical trials in early AD, we assessed rates of eligibility among racial and ethnic groups controlling for other demographic covariates. Each trial incorporated positron emission tomography and/or cerebrospinal fluid to evaluate brain amyloid pathology, as well as typical eligibility criteria used in early AD trials. RESULTS: Across the trials, 10,804 US participants were screened: 193 (2%) were of Hispanic ethnicity and Black race, 2,624 (25%) were of Hispanic ethnicity and White race, 118 (1%) were of non-Hispanic ethnicity (NH) and Asian race, 696 (7%) were of NH ethnicity and Black race, and 7,017 (65%) were of NH ethnicity and White race. Data from 156 participants who did not fit into these categories were excluded. Accounting for age, sex, and trial and using NH White participants as a reference group, we observed higher probabilities of ineligibility for amyloid biomarker criteria among Hispanic Black (odds ratio [OR] = 3.20, 95% confidence interval [CI] = 2.11-4.88), Hispanic White (OR = 4.15, 95% CI = 3.58-4.83), NH Asian (OR = 2.35, 95% CI = 1.23-4.55), and NH Black (OR = 3.75, 95% CI = 2.80-5.06) participants. INTERPRETATION: Differential eligibility may contribute to underrepresentation of some minoritized racial and ethnic groups in early AD trials. Amyloid biomarker eligibility is a requirement to confirm the diagnosis of AD and for treatment with amyloid-lowering drugs and differed among racial and ethnic groups. ANN NEUROL 2024;95:288-298.
引用
- Grill JD, Flournoy C, Dhadda S, et al. Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease. Ann Neurol. 2023. PMID: 37830926. doi:10.1002/ana.26819
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。